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Abstract
Introduction In hereditary tyrosinemia type 1 (HT1) patients,
the dose of NTBC that leads to the absence of toxic metabo-
lites such as succinylacetone (SA) is still unknown.
Therefore, the aims of this study were to investigate the var-
iation and concentrations of 2-(2-nitro-4-trifluormethyl-ben-
zyl)-1,3-cyclohexanedione (NTBC) during the day in relation
to the detection of SA, while comparing different dosing
regimens.
Methods All patients were treated with NTBC (mean
1.08 ± 0.34 mg/kg/day) and a low phenylalanine-tyrosine
diet. Thirteen patients received a single dose of NTBC and
five patients twice daily. Home bloodspots were collected
four times daily for three consecutive days measuring
NTBC and SA concentrations. Statistical analyses were per-
formed by using mixed model analyses and generalized linear
mixed model analyses to study variation and differences in
NTBC concentrations and the correlation with SA,
respectively.
Results NTBC concentrations varied significantly during the
day especially if NTBC was taken at breakfast only
(p = 0.026), although no significant difference in NTBC con-
centrations between different dosing regimens could be found
(p = 0.289). Momentary NTBC concentrations were negative-
ly correlated with SA (p < 0.001). Quantitatively detectable
SAwas only found in subjects with once daily administration
of NTBC and associated with momentary NTBC concentra-
tions <44.3 μmol/l.
Discussion NTBC could be less stable than previously con-
sidered, thus dosing NTBC once daily and lower concentra-
tions may be less adequate. Further research including more
data is necessary to establish the optimal dosing of NTBC.
Keywords Tyrosinemia type 1 . NTBC . Succinylacetone .
SA
Introduction
Hereditary tyrosinemia type 1 (HT1; McKusick 276,700) is a
rare, autosomal recessive metabolic disorder caused by a defi-
ciency of fumarylacetoacetate hydrolase, the last enzyme in the
tyrosine catabolism pathway. This deficiency results in accu-
mulation of toxic metabolites, such as maleylacetoacetate,
fumarylacetoacetate (FAA), succinylacetoacetate, and
succinylacetone (SA). The accumulation of these toxic metab-
olites can cause liver failure, hepatocellular carcinoma (HCC),
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renal tubulopathy, cardiomyopathy, and porphyria-like-
syndrome with neuropathy (van Spronsen et al 1994,
Larochelle et al 2012, de Laet et al 2013). Life expectancy in
HT1 patients is low when they are treated with a low phenyl-
alanine and tyrosine diet only (van Spronsen et al 1994, de Laet
et al 2013).
The course of the disease has changed remarkably since
1992, when it was observed that 2-(2- nitro-4-trifluormethyl-
benzyl)-1,3-cyclohexanedione (NTBC) prevents the accumu-
lation of toxic metabolites by blocking the tyrosine degrada-
tion at the level of 4-OH-phenylpyruvate dioxygenase, prox-
imal from the primary enzymatic defect (Lindstedt et al 1992).
This in turn prevents the formation of toxic products, leading
to resolution of liver failure and porphyria-like-syndrome and
a substantial reduction in HCC (Holme and Lindstedt 1998,
Holme and Lindstedt 2000). Consequently, life expectancy in
HT1 has considerably improved (Larochelle et al 2012).
However, as NTBC blocks the tyrosine degradation pathway,
tyrosine concentrations increase, so restriction of dietary tyro-
sine and phenylalanine is still necessary (Russo et al 2001, de
Laet et al 2013).
Despite improved treatment with NTBC, previous reports
indicate that HT1 patients are still at risk for developing he-
patocellular carcinoma (van Spronsen et al 2005, Koelink et al
2006, van Ginkel et al 2015). This may be related to subopti-
mal treatment with NTBC. Accumulation of FAA causes the
development of HCC (Jorquera and Tanguay 1997, Jorquera
and Tanguay 1999). As SA can be used as a surrogate marker
of toxicity in the liver, we should aim at the lowest NTBC
dose associated with the lowest possible SA concentration in
blood and urine (Grompe et al Grompe 2001, de Laet et al
2013, Mayorandan et al 2014).
The current dosing recommendation is twice a day as spec-
ified by the manufacturers (Orfadin [package insert] 2017).
However, a single dose of NTBC per day was suggested in
HT1 patients (at 1 mg/kg/day), based on the long half-life of
54 h observed in healthy adults and the finding that in HT1
patients NTBC concentrations tended to be stable for at least
24 h with a single dose regime (Hall et al 2001, Schlune et al
2012, de Laet et al 2013).
However, in practice, blood NTBC levels are reported
to vary greatly between individuals (Schlune et al 2012, de
Laet et al 2013) and within the same patients with time.
As a consequence, target blood NTBC concentrations are
not well established. Therefore, the research questions of
this study were: (1) Do mean NTBC concentrations and
daytime variation of NTBC differ between different NTBC
dosing regimens? (2) What is the occurrence of elevated
SA with different NTBC dosing regimens? Answering
these research questions may help to suggest an optimal
dosing regimen and to indicate a minimal NTBC concen-




In total, 18 HT1 patients (13 males, five females; mean age
9.3 ± 6.8 years; range 1–20 years) were studied. Five patients
were diagnosed and treated in the University Medical Center
Groningen and 13 patients in the Birmingham’s Children’s
hospital (UK). Except for having HT1, patients were healthy,
did not have signs suggestive of liver dysfunction, HCC or
renal tubulopathy. Patients with HT1were includedwhen they
were older than one year of age and treated with NTBC and a
tyrosine and phenylalanine restricted diet. All subjects main-
tained their regular NTBC dose and dosing regime and diet
with individually tailored natural protein intake, titrated ac-
cording to target blood tyrosine concentrations (200–
400 μmol/L) during the study period. In five patients, the total
daily dose of NTBC was divided into two doses, while the
other 13 patients were given a single daily dose of NTBC.
Stable dietary protein and energy intakes were maintained.
Phenylalanine supplementation was not prescribed to any pa-
tient during the study period.
The study was approved by the medical ethical committee
of the Univers i ty Medical Center Groningen in
The Netherlands and a favorable opinion was given by the
South Birmingham ethical committee for Birmingham
Children’s Hospital, UK. All HT1 caregivers gave written
informed consent for this study and children gave assent if
age and understanding was appropriate.
Study design
In this observational prospective study, patients or the care-
givers of patients took blood spot samples on blood cards at
home four times daily (pre-breakfast, pre-midday meal, pre-
evening meal, and pre-bedtime) for three consecutive days. In
total, 12 blood spots were taken for each subject and overall,
214 samples were collected (from two subjects, one sample
was not obtained). The caregivers or patients were trained to
take blood spots themselves.
Analyses of blood results
All blood spots were stored in a sealed plastic bag with a silica
sachet at −20 °C until analysis. Blood spot NTBC and SA
concentrations were measured in the University Medical
Center Groningen using an ultra-high performance liquid
chromatography method coupled to a triple quadrupole mass
spectrometer (UHPLC-MS/MS). The detection limit of blood
spot SA was 0.2 μmol/l with a limit of quantification of
0.6 μmol/L. A detailed description of the method, including
validation, is provided as Supplementary material.
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Statistics
Baseline differences between the different treatment groups
(NTBC taken at breakfast, evening meal or both) were studied
using one-way ANOVA analysis. The variation of NTBC dur-
ing the day was studied using mixed model analyses, by con-
sidering the moment of NTBC intake (at breakfast, evening
meal or both), the moment of blood sampling and an interac-
tion between both. To further study differences in NTBC con-
centrations during the day between subjects with different
treatment regimens (taking NTBC at breakfast, at evening
meal or both) univariate mixed model analysis was done. To
study the correlation between momentary NTBC and SA con-
centrations ≥0.6 μmol/L, generalized linear mixed model
analyses was performed. Afterwards, mean NTBC concentra-
tions during the study period and the number of samples with
SA ≥ 0.6 μmol/L per patient were calculated and Spearman
correlational analyseswere performed between both variables.
In addition, differences in mean NTBC concentrations for
patients with and without quantitatively detectable SA during
the study period were analyzed using an independent sample
T-test. Statistical analyses were conducted with the statistical
program SPSS 22 (IBM, Chicago, Illinois). A p-value of
<0.05 was considered statistically significant.
Results
Subject characteristics are given in Table 1. The subjects were
divided into three groups depending on their moment of intake
of NTBC. For the group who received NTBC once daily
(N = 13), six subjects received NTBC at breakfast and seven
subjects received NTBC at the evening meal. The subjects
taking NTBC twice daily received their NTBC both at break-
fast and at the evening meal. The total daily NTBC dose (in
mg/kg/day) did not significantly differ between the three
groups of subjects (subjects receiving NTBC in a single dose
or in two doses) (p = 0.13). Despite that natural protein intake,
total protein intake, and tyrosine concentrations seemed to
differ, none reached statistical significance (p = 0.12,
p = 0.13, and p = 0.13, respectively). Figure 1 shows the
variation of NTBC during the day, comparing subjects who
received a single dose of NTBC, at breakfast or evening meal,
and subjects who divided their NTBC in two doses a day.
Mixed model analyses showed a significant interaction be-
tween the timing of NTBC intake and the moment of blood
sampling (p = 0.041), indicating that the pattern of NTBC
concentrations during the day was different between the three
different groups. Post hoc analyses showed that the group of
subjects taking NTBC at breakfast had a significant variation
of NTBC concentrations especially in the morning
(p = 0.026). No significant variation in NTBC concentrations
during the day was seen in both other groups (subjects who
took two doses of NTBC and subjects who took a single dose
of NTBC at the evening meal).
Figure 1 also shows the mean NTBC concentrations during
the day comparing the three different groups of subjects.
Mixed model analyses were done to compare NTBC concen-
trations of the three different subject groups at all four differ-
ent timing moments of blood sampling during the day, but no
significant differences were found. However, NTBC concen-
trations tended to be higher during the day when subjects
received NTBC twice daily as also shown in Table 2. Of note,
one patient lived a far distance from the clinical center. The
blood spots were taken in a warm climate and transport took
more time. This subject had very low levels of NTBC
(mean = 16.8 ± 3.9) that deviated from the NTBC concentra-
tions of other subjects who were treated in the same center and
treated similarly (Table 2). When excluding this patient, the
tendency toward differences in NTBC concentrations in the
morning between the group taking NTBC at breakfast and the
group taking NTBC twice daily became statistically signifi-
cant (p = 0.016).
No quantitatively detectable SAwas found in subjects ad-
ministered twice daily NTBC. However, SA ≥ 0.6 μmol/L
was found in > 50% of subjects (seven of the 13 subjects)
who took NTBC once daily. Three of them took their NTBC
at breakfast and four subjects took their NTBC at the evening
Table 1 Patient characteristics for the different groups receiving NTBC as a single dose or divided in two doses a day
HT1 NTBC once daily (n = 13) HT1 NTBC twice daily (n = 5)
NTBC at breakfast (n = 6) NTBC at evening meal (n = 7)
Mean age 8.5 (± 4.1 year) 8.8 (± 3.9 year) 9.9 (± 7.4 year)
Gender 4:2 (m/f) 4:3 (m/f) 4:1 (m/f)
NTBC intake (mg/kg/day) 1.14 ± 0.50 0.99 ± 0.30 1.15 ± 0.24
Total protein intake (g/kg/day) 2.59 ± 0.83 2.49 ± 0.55 1.72 ± 0.76
Natural protein intake (g/kg/day) 0.79 ± 0.32 0.73 ± 0.36 0.43 ± 0.06
Mean tyrosine (μmol/L) 356 ± 47.5 423 ± 98.6 312 ± 115
Mean phenylalanine (μmol/L) 40.5 ± 9.4 43.0 ± 10.5 39.0 ± 11.3
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meal. In total, SA ≥ 0.6 μmol/L was found in 54 of 156
samples. The median SA concentration in the samples with
SA above the limit of quantification was 0.7 μmol/L (range:
0.6–1.2 μmol/L). There was no significant difference in the
age of subjects with SA concentrations ≥0.6 μmol/L and sub-
jects who did not (p = 0.724). Neither was there a specific time
during the day that SA could be found, as the number of
samples with SA was equally distributed across the different
sample moments during the day.
Generalized linear mixed model analyses showed that in
individual samples, momentary NTBC concentrations were
negatively correlated to SA concentrations ≥0.6 μmol/
L(β = −0.062 p = 0.000). In the samples where SA was ob-
served, the NTBC concentrations varied between 14.2–
44.3 μmol/L. When the NTBC concentration in momentary
samples were >44.3 μmol/L, no quantitatively detectable SA
was found.
To further analyze the correlation between NTBC concen-
trations and the samples with quantitatively detectable SA,
mean NTBC concentrations during the study period were cal-
culated and related to the samples with quantitatively detect-
able SA. Figure 2a shows that if one sample in an individual
patient showed a SA concentration above the detection limit
of quantification, SA concentrations were usually quantifiable
during a large part of the study. Correlational analyses re-
vealed a significant negative correlation between the mean
NTBC concentration during the study period and the number
of samples with quantitatively detectable SA per patient
(ρ = −0.514, p = 0.029). In addition, Fig. 2a shows that when
mean NTBC concentrations during the study period were
>35 μmol/L, no SA ≥ 0.6 μmol/L was found. Figure 2b shows
that the mean NTBC concentrations during the study period
were significantly higher in the subjects who did not show any
quantitatively raised SA concentrations (mean = 35.6 ± 8.5)
compared to subjects where SAwas quantifiable at least once
(mean = 26.5 ± 6.0) (p = 0.026).
Discussion
With the dosing regimen of NTBC as advised by de Laet (de
Laet et al 2013), increased SA concentrations are still found.
This could possibly indicate a sub-optimal block, of course
acknowledging the fact that not detecting SA may be due to
technical reasons rather than the absence of SA. Therefore, the
aims of this study were to investigate NTBC concentrations
and its variation during the day and to study SA in relation to
the NTBC dosage. By doing this, we investigated if a specific
Fig. 1 Mean NTBC
concentrations at the different
sample moments during the day.
Mean NTBC concentrations
during the day in the group of
HT1 patients, divided based on
different treatment regimes.
Especially showing variation in
the group of patients taking their
NTBC at breakfast only
Table 2 MeanNTBC concentrations (+ SD) inμmol/L during the day in the different treatment groups, with significantly lower NTBC concentrations
in the morning in the group of patient taking NTBC at breakfast only, compared to patients who take NTBC twice a day (after exclusion of outlier).
*p < 0.05
NTBC single dose treatment NTBC two doses a day
NTBC at breakfast (n = 6) NTBC at evening meal (n = 7) All patients (n = 5) Excluding outlier (n = 4)
Pre-breakfast sample 26.2 ± 7.8* 31.0 ± 8.9 33.8 ± 13.2 38.9 ± 8.9
Pre-midday sample 33.0 ± 9.7 30.5 ± 12.5 35.3 ± 12.0 39.9 ± 8.3
Pre-evening meal sample 34.4 ± 12.5 30.6 ± 11.4 32.5 ± 9.7 36.0 ± 7.3
Bedtime sample 33.6 ± 9.2 32.0 ± 10.1 33.8 ± 12.9 38.0 ± 10.8
Overall 31.8 ± 10.2 31.0 ± 10.6 33.8 ± 11.8 38.1 ± 8.7
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NTBC dosing regimen could be advised in HT1 patients. The
main findings were: (1) NTBC concentrations varied during
the day, particularly when NTBC was given once daily, and
especially when taken at breakfast only. (2) NTBC concentra-
tions tended to be higher andmore stable in the patients receiv-
ing two doses of NTBC a day, but this did not reach statistical
significance, and (3) NTBC concentrations were negatively
correlated to SA. Quantitatively detectable SAwas only found
in patients who took one single dose of NTBC, especially
when momentary NTBC concentrations were <44.3 μmol/L.
Before discussing the results in more detail, four method-
ological issues need to be addressed. Firstly, this study was an
observational study and would have had a higher power if
both treatment regimens were being tested in the same patients
using a cross-over design. Secondly, the study was performed
at patient’s homes. All blood spots were sent together after
finishing the complete study and were analyzed at the
University Medical Center Groningen and stored at −20 °C
until analyzed. However, one of the patients receiving two
daily doses of NTBC lived in a warm climate 3500 km from
the center where he was treated, resulting in a time delay for
receipt of blood spot samples. Although it was found that
NTBC concentrations in blood spots were stable for at least
a period of 1 month when stored at room temperature (La
Marca et al 2012), our laboratory experience revealed that
NTBC and SA concentrations are more stable when stored
at low temperature. Further studies are needed to explore
whether different storage conditions (like warm climate or a
longer duration until analysis) influence NTBC and SA con-
centrations in dried blood spots. Thirdly, especially our find-
ings on SA concentrations may be influenced by the limit of
quantification rather than the exact SA concentration. Since
most subjects had SA levels below limit of quantification
using a lower limit of quantification for SA would have
resulted in different findings. Fourth, although not statistically
significant, total and natural protein intake in the group of
patients taking NTBC once daily seemed to be higher com-
pared to the group taking NTBC twice daily. Theoretically,
higher protein intake could result in higher tyrosine concen-
trations and a higher flux through the tyrosine degradation
pathway (Holme and Lindstedt 1998). However, tyrosine con-
centrations did not differ significantly as well.
Our results show a significant variation in NTBC concen-
trations during a 24-h period especially seen in patients who
took their NTBC as a single dose at breakfast. In this group a
drop of 21.3% in NTBC concentrations in < 20 h was observed
between the pre-midday and pre-breakfast sample. This con-
trasts with previous studies that indicated NTBC had a stability
of at least 24 h in HT1 patients, while in healthy adults even a
half-life of 54 h was found (Schlune et al 2012, Hall et al
2001). The variation in NTBC concentrations in our sample
at least suggests that biological availability was < 24 h and that
this could have implications regarding the detection of SA,
especially for subjects taking a single daily dose of NTBC.
When considering NTBC concentrations, our data indicate
a tendency toward lower NTBC concentrations for the pa-
tients receiving NTBC once daily in comparison with receiv-
ing NTBC twice daily rather than a statistically significant
difference. However, clear statistical significance was reached
when the subject with the long transport time of samples was
excluded as an apparent outlier probably due to differences in
pre-analytical conditions. This is in contrast to previous stud-
ies, which failed to show any differences between dosing
once, twice, and three times a day (Schlune et al 2012).
Both, momentary and mean NTBC concentrations during
the study period were negatively correlated to SA. The differ-
ence between momentary and mean NTBC concentrations
without quantitatively detectable SA is expected to be caused
Fig. 2 Mean NTBC concentrations and its relation to SA. aMean NTBC
concentrations during the study period graphically displaced against the
number of samples with SA ≥ 0.6 μmol/L. The linear line represents the
negative correlation between the number of samples with SA ≥ 0.6 μmol/
L and mean NTBC concentrations. b Mean NTBC concentrations in
patients with and without any sample with quantitatively detectable SA
(≥ 0.6 μmol/L) during the study period
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by the long half-life of SA in plasma (Holme and Lindstedt
1998). Quantitatively detectable SA possibly indicates a peri-
od of lower NTBC concentrations before the moment of blood
sampling. Most importantly, in our study, SA was not found
when momentary NTBC concentrations were above
44.3 μmol/L, which is in accordance with the results of
Herebian et al (2009) who concluded that NTBC concentra-
tions should be above 50 μmol/L (Herebian et al 2009).
Acknowledging the importance of maintaining SA concen-
trations as low as possible, our data seem to indicate that dosing
NTBC twice daily might be better than once daily. Our data
also suggest that higher NTBC concentrations are related to
lower SA concentrations. Before stronger conclusions can be
drawn, further studies with more data on the dosing of NTBC
and related SA concentrations are needed. Therefore, it is man-
datory to monitor NTBC and SA concentrations frequently,
preferably by home blood spot sampling for which measure-
ment can be performed in expert centers for this disease.
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